Leerink Swann Reiterates “$67.00” Price Target for EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences (NASDAQ:EXAS) has been given a $67.00 price objective by equities research analysts at Leerink Swann in a research note issued on Friday, February 9th. The brokerage presently has a “buy” rating on the medical research company’s stock. Leerink Swann’s target price suggests a potential upside of 37.13% from the stock’s current price. Leerink Swann also issued estimates for EXACT Sciences’ Q4 2017 earnings at ($0.25) EPS, FY2017 earnings at ($1.06) EPS, Q1 2018 earnings at ($0.25) EPS, Q2 2018 earnings at ($0.20) EPS, Q4 2018 earnings at ($0.08) EPS, FY2018 earnings at ($0.67) EPS and FY2019 earnings at $0.29 EPS.

EXAS has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a research report on Tuesday, January 16th. Bank of America set a $56.00 price target on shares of EXACT Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. Canaccord Genuity upgraded shares of EXACT Sciences to a “buy” rating and set a $60.00 price target for the company in a report on Tuesday, October 31st. BidaskClub downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Finally, William Blair reiterated a “buy” rating on shares of EXACT Sciences in a report on Tuesday, January 2nd. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. EXACT Sciences has an average rating of “Buy” and an average target price of $52.84.

Shares of EXACT Sciences (NASDAQ:EXAS) traded down $0.28 during trading on Friday, reaching $48.86. 1,230,000 shares of the company’s stock were exchanged, compared to its average volume of 3,370,000. The stock has a market cap of $5,850.00, a P/E ratio of -42.49 and a beta of 0.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. EXACT Sciences has a 52 week low of $19.54 and a 52 week high of $63.60.

In related news, SVP D Scott Coward sold 1,665 shares of the stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total value of $87,479.10. Following the sale, the senior vice president now directly owns 37,558 shares of the company’s stock, valued at approximately $1,973,297.32. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Kevin T. Conroy sold 134,057 shares of the stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total transaction of $7,976,391.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 764,182 shares of company stock worth $40,574,047. 4.00% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Advisor Group Inc. grew its stake in EXACT Sciences by 0.8% in the 2nd quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock valued at $270,000 after acquiring an additional 65 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of EXACT Sciences by 5.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,640 shares of the medical research company’s stock worth $341,000 after purchasing an additional 511 shares during the last quarter. Amalgamated Bank boosted its stake in shares of EXACT Sciences by 6.0% during the 3rd quarter. Amalgamated Bank now owns 14,964 shares of the medical research company’s stock worth $705,000 after purchasing an additional 845 shares during the last quarter. Raymond James & Associates boosted its stake in shares of EXACT Sciences by 1.2% during the 4th quarter. Raymond James & Associates now owns 98,777 shares of the medical research company’s stock worth $5,190,000 after purchasing an additional 1,168 shares during the last quarter. Finally, American International Group Inc. boosted its stake in shares of EXACT Sciences by 1.5% during the 4th quarter. American International Group Inc. now owns 79,238 shares of the medical research company’s stock worth $4,163,000 after purchasing an additional 1,207 shares during the last quarter. 83.12% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://ledgergazette.com/2018/02/18/exact-sciences-exas-given-a-67-00-price-target-by-leerink-swann-analysts.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply